On 12 November 2019 the European Data Protection Board (EDPB) has released the fourth, updated version of the Guidelines 3/2018 on the territorial scope of the General Data Protection Regulation (GDPR), adopted after consultation with the public. As in previous editions, the emphasis is on the practical application of two criteria for the extension of the action of the GDPR to a controller or processor: an „establishment“ of a controller or processor in the EU and „targeting“ (the targeting of activities).
Establishment Criterion of Activities in the EU
In the context of an establishment of a controller or processor in the EU, it is recommended to use the three-step test:
1. The presence of an establishment in the EU, which equals the implementation of effective and real activity through stable arrangements, regardless of its legal form (subsidiary, office, branch). In particular, the stable presence of a single employee in the EU, if he performs his functions for a certain time and steadily, could be sufficient to consider that an entity has an establishment in the EU.
For example, a pharmaceutical company registered in Australia has a representative office in Berlin, that is involved in all activities, including the promotion of medicines in the EU.
2. The processing of personal data is carried out in the context of the activities of such an establishment. Most importantly, there are income-generating in the EU and the relationship of a controller or processor outside of the EU with its establishment in the EU. If an inextricable link is established between the processing of personal data of a controller or processor outside of the EU and acting for an EU-based customer, such a controller or processor will be subject to the GDPR.
For example, it is precisely by this criterion that the GDPR will not apply to a cosmetic company that operates through its website, available in different EU languages, if it does not have an office, representative office or other stable presence in the EU.
3. The processing of personal data is carried out in the context of the activities of such an establishment, regardless of whether the personal data itself is processed in the EU.
For example, personal data related to the clinical trials of a pharmaceutical company registered in France are processed in the Japanese subsidiary of such a company.
If these steps are applicable, then the GDPR applies to the appropriate controller or processor.
Targeting (the targeting of activities) of a controller or processor
In the absence of an establishment in the EU, the GDPR may apply to legal entities for ist extraterritorial action. In this case, the targeting criterion (the targeting of activities) of a controller or processor is applied.
The targeting of the activities is determined by two factors:
To understand the targeting criteria applied to your company, you need to answer the following questions:
The consequences of non-compliance with the GDPR requirements for companies
The GDPR distinguishes 2 categories of administrative fines that EU supervisors can impose for violating the GDPR:
1. Up to 10 million Euros or, in the case of an enterprise, up to 2% of the total global annual turnover for the previous financial year, depending on how much is higher, for the following violations:
2. Up to 20 million Euros or, in the case of an enterprise, up to 4% of the total global annual turnover for the previous financial year, depending on how much is higher, for the following violations:
For all questions about the need to implement the GDPR requirements for the activities of your company, please contact Oleksiy Bezhevets, a partner, bezhevets@l-a.com.ua.
The event focused on the transformation of Ukraine's intellectual property sector on its path toward European integration.
Improving access to safe and affordable medicines for the Ukrainian population is one of the Government of Ukraine's top priorities. SAFEMed Activity (2017-2025) has supported this effort by appIying health system strengthening best practices.
The Ministry of Health website has posted a notice about the release of a revised draft order of the Ministry of Health ‘On Approval of Amendments to Certain Re
On 25 September, a webinar was held on the topic: ‘180 days of new drug price regulation. Results, prospects and practical advice.’ The event was organized by LA Law Firm in partnership with Proxima Research International.